News

Ligocyte participates in Kennedy Round Table meeting on Bioterrorism

BOZEMAN, MT LigoCyte Pharmaceuticals, Inc. http://www.ligocyte.com announced today that it participated in a round table meeting on bioterrorism at the invitation of Senator Edward M. Kennedy. LigoCyte’s CEO, Michael McCue, participated in the meeting with selected representatives of biotechnology and pharmaceutical companies who gathered to discuss ways in which industry can provide accelerated solutions to the nation’s needs in the face of bioterrorist events.

LigoCyte Pharmaceuticals applies its expertise in leukocyte biology to the development of therapeutics in cell targeting, cell signaling and cell trafficking. The company has a number of ongoing development programs in inflammatory and infectious diseases, and is developing technologies for the enhanced delivery of antigens to direct the immune response to provide protection against invasive organisms.

LigoCyte is currently funded under a Department of Defense program to develop oral and nasal vaccines against bioterrorist agents, including Anthrax. The company’s non-viral mucosal targeting technology holds the potential to offer vaccine constructs appropriate for field use by the military as well as for use by civilian populations, with greatly enhanced mucosal protection against infection. LigoCyte’s oral delivery of vaccines also addresses issues associated with widespread immunization in less developed nations.

LigoCyte, established in 1998, is headquartered in Bozeman, Montana. For more information, please visit LigoCyte’s web site at http://www.ligocyte.com.

Except for historical information, the matters discussed in this news release contain forward-looking statements regarding future events that involve risks and uncertainties which could cause actual results to differ materially from the statements made. These risks and uncertainties include, among other things, the levels and timing of payments under LigoCyte’s collaborative agreements, uncertainties relating to LigoCyte’s ability to successfully discover, develop, test, secure regulatory approval of and finance any of its current or future drug candidates, uncertainties about LigoCyte’s ability to obtain new corporate collaborations on satisfactory terms, and the risk that LigoCyte or its partners will not be able to successfully commercialize the products developed from LigoCyte’s research and development.

Contact: Robert R. Goodwin, Ph.D.
Executive VP, Chief Operating Officer
LigoCyte Pharmaceuticals, Inc.
Phone: 406.585.2733
FAX: 406.585.2766
[email protected]

http://www.ligocyte.com/articleview.asp?ID=33

Posted in:

Sorry, we couldn't find any posts. Please try a different search.

Leave a Comment

You must be logged in to post a comment.